Yang X et al. |
Effects of TGF-β1 on OPG/RANKL expression of cementoblasts and osteoblasts are similar without stress but different with mechanical compressive stress. |
2015 |
ScientificWorldJournal |
pmid:25685846
|
Zhang Q et al. |
Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. |
2013 |
ScientificWorldJournal |
pmid:24222748
|
Teitelbaum SL |
Bone resorption by osteoclasts. |
2000 |
Science |
pmid:10968780
|
Wickelgren I |
Mining the genome for drugs. |
1999 |
Science |
pmid:10475849
|
Warren JT et al. |
Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. |
2014 |
Sci Signal |
pmid:25140055
|
Zang L et al. |
The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis. |
2015 |
Sci Rep |
pmid:26671549
|
Schiro A et al. |
Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. |
2015 |
Sci Rep |
pmid:26564003
|
Mizuno M et al. |
Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. |
2015 |
Sci Rep |
pmid:26561427
|
Nemeth ZK et al. |
Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. |
2015 |
Sci Rep |
pmid:26459001
|
Wang B et al. |
Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. |
2015 |
Sci Rep |
pmid:26329493
|
Kao SY and Stankovic KM |
Transactivation of human osteoprotegerin promoter by GATA-3. |
2015 |
Sci Rep |
pmid:26216189
|
Hope S et al. |
Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. |
2013 |
Schizophr. Res. |
pmid:23403415
|
Dieset I et al. |
Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. |
2012 |
Schizophr. Res. |
pmid:22817875
|
Gehrke T et al. |
Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. |
2003 |
Scand. J. Rheumatol. |
pmid:14690142
|
Spelling P et al. |
Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? |
2008 Nov-Dec |
Scand. J. Rheumatol. |
pmid:18802807
|
Sennels H et al. |
Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. |
2008 Jul-Aug |
Scand. J. Rheumatol. |
pmid:18612923
|
Feuerherm AJ et al. |
Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. |
2001 |
Scand. J. Rheumatol. |
pmid:11578019
|
Reenaers C et al. |
Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. |
2008 |
Scand. J. Gastroenterol. |
pmid:18942021
|
Yilmaz Y et al. |
Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. |
2010 |
Scand. J. Clin. Lab. Invest. |
pmid:20942739
|
Grauslund J et al. |
Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? |
2010 |
Scand. J. Clin. Lab. Invest. |
pmid:20205614
|
Bjerre M et al. |
Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. |
2014 |
Scand. J. Clin. Lab. Invest. |
pmid:25026506
|
Sennels HP et al. |
Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. |
2007 |
Scand. J. Clin. Lab. Invest. |
pmid:17852826
|
Knudsen ST et al. |
Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. |
2007 |
Scand. J. Clin. Lab. Invest. |
pmid:17365993
|
Altinova AE et al. |
Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. |
2011 |
Scand. J. Clin. Lab. Invest. |
pmid:21486111
|
Muñoz-Calvo MT et al. |
Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. |
2007 |
Scand. J. Clin. Lab. Invest. |
pmid:17558893
|
Hosbond SE et al. |
Osteoprotegerin as a marker of atherosclerosis: a systematic update. |
2012 |
Scand. Cardiovasc. J. |
pmid:22506827
|
Stenman UH et al. |
Prognostic value of serum markers for prostate cancer. |
2005 |
Scand J Urol Nephrol Suppl |
pmid:16019759
|
Mohamed GB and Abdel-Latif EA |
Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. |
2011 |
Saudi J Kidney Dis Transpl |
pmid:21912025
|
Takayanagi H |
[Crosstalk between the immune and skeletal system]. |
2003 |
Ryumachi |
pmid:14598653
|
Gurban CV and Mederle O |
The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. |
2011 |
Rom J Morphol Embryol |
pmid:22119834
|
Grigorie D et al. |
Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. |
2003 |
Rom J Intern Med |
pmid:15526523
|
Grzegorzewska AE and MÅ‚ot M |
Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631341
|
Grzegorzewska AE and MÅ‚ot M |
Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631342
|
Naumnik W et al. |
Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15638385
|
Fukagawa M et al. |
[PTH and bone metabolism in chronic dialysis patients]. |
2001 |
Rinsho Byori |
pmid:11307321
|
Haynes DR et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. |
2001 |
Rheumatology (Oxford) |
pmid:11426018
|
Kim HR et al. |
Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). |
2006 |
Rheumatology (Oxford) |
pmid:16567356
|
Corallini F et al. |
The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. |
2009 |
Rheumatology (Oxford) |
pmid:19168833
|
Smith MD |
Comment on review on T cells in bone biology. |
2004 |
Rheumatology (Oxford) |
pmid:15448222
|
Pettit AR et al. |
RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. |
2006 |
Rheumatology (Oxford) |
pmid:16490750
|
Bezerra MC et al. |
Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. |
2005 |
Rheumatology (Oxford) |
pmid:16219645
|
Kwan Tat S et al. |
Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. |
2009 |
Rheumatology (Oxford) |
pmid:19762475
|
Castellino G et al. |
The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? |
2010 |
Rheumatology (Oxford) |
pmid:20299382
|
Varsani H et al. |
Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). |
2003 |
Rheumatology (Oxford) |
pmid:12649407
|
Engvall IL et al. |
Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. |
2013 |
Rheumatology (Oxford) |
pmid:23275387
|
Huang CH et al. |
Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. |
2011 |
Rheumatology (Oxford) |
pmid:20974615
|
Hofbauer LC et al. |
Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. |
2006 |
Rheumatology (Oxford) |
pmid:16574701
|
Breland UM et al. |
Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. |
2010 |
Rheumatology (Oxford) |
pmid:20231178
|
Haynes DR et al. |
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. |
2003 |
Rheumatology (Oxford) |
pmid:12509625
|
Harashima SI et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. |
2004 |
Rheumatology (Oxford) |
pmid:14963213
|
Xu S et al. |
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. |
2012 |
Rheumatol. Int. |
pmid:22057136
|
Skoumal M et al. |
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. |
2008 |
Rheumatol. Int. |
pmid:18075741
|
Kanbe K et al. |
Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. |
2012 |
Rheumatol. Int. |
pmid:21789615
|
Oelzner P et al. |
The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. |
2012 |
Rheumatol. Int. |
pmid:20821212
|
Rooney T et al. |
Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. |
2010 |
Rheumatol. Int. |
pmid:19847430
|
Hein GE et al. |
sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. |
2008 |
Rheumatol. Int. |
pmid:18172654
|
Stupphann D et al. |
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. |
2008 |
Rheumatol. Int. |
pmid:18369625
|
Yun HJ et al. |
Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. |
2009 |
Rheumatol. Int. |
pmid:19116717
|
Agarwal S et al. |
Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. |
2009 |
Rheumatol. Int. |
pmid:19052752
|
Zhou J et al. |
Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. |
2013 |
Rheumatol. Int. |
pmid:22948539
|
Keller KK et al. |
SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes. |
2013 |
Rheumatol. Int. |
pmid:22948540
|
Skoumal M et al. |
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. |
2005 |
Rheumatol. Int. |
pmid:15889303
|
Yao Y et al. |
Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. |
2013 |
Rheumatol. Int. |
pmid:23334376
|
Pamuk BO et al. |
Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. |
2013 |
Rheumatol. Int. |
pmid:23358733
|
Chen J et al. |
OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell. |
2012 |
Rheumatol. Int. |
pmid:22210270
|
Kwon SR et al. |
Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. |
2012 |
Rheumatol. Int. |
pmid:21833531
|
Upton AR et al. |
The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. |
2012 |
Rheumatol. Int. |
pmid:21259010
|
Rosa-Rañal M et al. |
[New paradigms in the regulation of bone metabolism]. |
2001 Jul-Aug |
Rev. Invest. Clin. |
pmid:11599485
|
Ciacli C et al. |
[Bone turnover markers evaluation in psoriatic arthritis]. |
2008 Jul-Sep |
Rev Med Chir Soc Med Nat Iasi |
pmid:20201244
|
Collantes Estévez E and González DomÃnguez J |
[Bone Paget's disease in the young adult]. |
2004 |
Rev Clin Esp |
pmid:15456600
|
Sasso GR et al. |
Elevated serum osteoprotegerin levels in women: friend or foe? |
2015 Nov-Dec |
Rev Assoc Med Bras (1992) |
pmid:26841162
|
Riancho JA and Delgado-Calle J |
[Osteoblast-osteoclast interaction mechanisms]. |
2011 |
Reumatol Clin |
pmid:21924211
|
Bogliolo L et al. |
Biomarkers and prognostic stratification in psoriatic arthritis. |
2012 |
Reumatismo |
pmid:22690385
|
Bai P et al. |
Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. |
2011 |
Respir. Res. |
pmid:22176920
|
Pobeha P et al. |
Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. |
2014 |
Respir Med |
pmid:24424018
|
Crisafulli A et al. |
Osteoprotegerin and bone mineral density in hemodiafiltration patients. |
2005 |
Ren Fail |
pmid:16152990
|
Heymann MF et al. |
OPG, RANK and RANK ligand expression in thyroid lesions. |
2008 |
Regul. Pept. |
pmid:18367263
|
Kadoglou NP et al. |
Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. |
2012 |
Regul. Pept. |
pmid:22982141
|
Minenna G et al. |
[RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. |
2005 |
Recenti Prog Med |
pmid:16229324
|
Kahl KG et al. |
Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. |
2006 Sep-Oct |
Psychosom Med |
pmid:17012519
|
Janda K et al. |
[The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients]. |
2012 |
Prz. Lek. |
pmid:23750431
|
Czyzewska-Buczyńska A et al. |
[Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients]. |
2013 |
Prz. Lek. |
pmid:24003660
|
Ziółkowska H and Roszkowska-Blaim M |
[Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. |
2006 |
Prz. Lek. |
pmid:16898492
|
Komosińska-Vassev K et al. |
[Osteoporosis--pathophysiology and laboratory diagnostic methods]. |
2010 |
Prz. Lek. |
pmid:21387765
|
Liu Z et al. |
Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. |
2004 |
Protein Pept. Lett. |
pmid:15327363
|
Helo S et al. |
Role of denosumab in prostate cancer. |
2012 |
Prostate Cancer Prostatic Dis. |
pmid:22370723
|
Quinn JE et al. |
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. |
2005 |
Prostate Cancer Prostatic Dis. |
pmid:15999121
|
Vandyke K et al. |
Androgen decreases osteoprotegerin expression in prostate cancer cells. |
2007 |
Prostate Cancer Prostatic Dis. |
pmid:17189957
|
Armstrong AP et al. |
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. |
2008 |
Prostate |
pmid:18008334
|
Corey E et al. |
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. |
2002 |
Prostate |
pmid:11992617
|
Hesry V et al. |
Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. |
2006 |
Prostate |
pmid:16541419
|
Burton DW et al. |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. |
2005 |
Prostate |
pmid:15389781
|
Zheng Y et al. |
Vitamin D deficiency promotes prostate cancer growth in bone. |
2011 |
Prostate |
pmid:21541977
|
Yonou H et al. |
Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. |
2007 |
Prostate |
pmid:17394194
|
Eaton CL et al. |
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. |
2004 |
Prostate |
pmid:15042606
|
Lin DL et al. |
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. |
2001 |
Prostate |
pmid:11351351
|
Poulsen RC et al. |
Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. |
2008 |
Prostaglandins Other Lipid Mediat. |
pmid:18077200
|
Li X et al. |
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. |
2002 |
Prostaglandins Other Lipid Mediat. |
pmid:12013525
|
Kuroyanagi G et al. |
(-)-Epigallocatechin gallate synergistically potentiates prostaglandin E2-stimulated osteoprotegerin synthesis in osteoblasts. |
2017 |
Prostaglandins Other Lipid Mediat. |
pmid:28163121
|
Wiercinska-Drapalo A et al. |
Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. |
2005 |
Prostaglandins Other Lipid Mediat. |
pmid:16303613
|